Can I get it?
Yes, if a doctor decides it is right for you. Mounjaro is authorised in the EU and can be prescribed after a medical review.
Mounjaro · SlovakiaPrescription only
Online medical consultation for Mounjaro in Slovakia.
An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription valid in any pharmacy in Slovakia. Consultation €25/month, refunded if the doctor decides it is not safe to prescribe.
- Once-weekly pen
- Dual GIP/GLP-1 receptor action
- Doctor-supervised, step-wise escalation
€25/monthFull refund if a review is not approved
Medication, if prescribed, is dispensed and paid for separately at a pharmacy.
IN PLAIN TERMS
What Mounjaro is, and how to get treatment
Mounjaro (tirzepatide) is a once-weekly injection for weight management. It copies two gut hormones — GIP and GLP-1 — which together reduce appetite, slow how quickly your stomach empties, and help steady your blood sugar. It is authorised across the EU and is prescribed by licensed doctors when clinically appropriate.
Mounjaro has been authorised for use in the EU since 15 September 2022, so a licensed doctor can prescribe it when it is clinically appropriate for you.
What can I take instead?
Our doctors review every Weight loss option and recommend what fits your history and goals.
See all Weight loss optionsWhat do the studies show?
Every trial behind Mounjaro is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.
Jump to the studiesLocal consultation facts
Can I get Mounjaro in Slovakia?
Yes. Residents of Slovakia can request an online doctor consultation about Mounjaro with Hi-Doctor. A licensed EU doctor reviews the case and issues a prescription only when clinically appropriate. If approved, the EU prescription arrives as a PDF for a pharmacist in Slovakia, who dispenses the locally marketed equivalent containing Tirzepatide.
Availability
Mounjaro is available to residents of Slovakia through the online consultation. A prescription follows only if the doctor approves it.
- Country
- Slovakia
- Language of service
- Spanish and English
- Prescription turnaround
- Within 24 hours, only if the doctor approves
- Honoured locally
- PDF honoured locally for an equivalent containing Tirzepatide
How the EU prescription works where you are: In Slovakia, show the approved prescription PDF to a pharmacist. They honour it under EU cross-border rules and dispense the locally marketed equivalent containing Tirzepatide.
VERIFIED EVIDENCE
Mounjaro: evidence and regulatory guide.
Mounjaro contains tirzepatide, an EU-authorised prescription medicine. The data below separate its regulatory status from the pivotal trial result.
WHAT IT IS
How it works
Tirzepatide is a once-weekly dual agonist that activates GIP and GLP-1 receptors. It has no glucagon component.
- GIP
- GLP-1
DEVELOPMENT STAGE
EU-authorised medicine
The EMA marketing authorisation has been valid across the EU since 15 September 2022 under EMEA/H/C/005620.
Trial register1 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| SURMOUNT-1NCT04184622 | Obesity or overweight without diabetes | 2,539 | Read out | 2022 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
SURMOUNT-1, NEJM 2022;387(3):205-216 · DOI: 10.1056/NEJMoa2206038| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| Placebo | −3.1% | 72 |
| 5 mg | −15.0% | 72 |
| 10 mg | −19.5% | 72 |
| 15 mg | −20.9% | 72 |
Peer-reviewed SURMOUNT-1, N=2,539, 72 weeks. This was a separate trial with its own population, sites and placebo response.
Sources
Last reviewed 2026-07-27
FormPre-filled injection pen
FrequencyOnce a week
ResultsGradual, over months
StatusPrescription only
About
What is Mounjaro?
Active ingredient: Tirzepatide · Dosages: 2.5 – 15 mg / week
Tirzepatide is a dual receptor agonist — it acts on the GLP-1 and GIP gut-hormone receptors at the same time. In clinical trials this translates into larger average weight loss than mono-agonist GLP-1s in adults with obesity.
It's a chronic treatment for as long as it's beneficial and safe: the doctor reviews your response every 3 months and decides with you whether to continue, adjust or stop. Discontinuation is gradual and paired with a maintenance plan.
How it works in the body
By activating two receptors at once, tirzepatide reinforces satiety signals, slows stomach emptying and helps regulate the insulin response — so you tend to eat less without counting every calorie.
How it helps
Three ways it supports weight loss.
Dual action
Works on two gut-hormone receptors (GLP-1 + GIP), not just one.
Reinforces satiety
Hunger eases and fullness lasts longer after smaller meals.
Reviewed quarterly
Your doctor reassesses response and tolerance every 3 months before renewing.
What to expect
A step-wise, supervised escalation.
The dose is escalated step-wise (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) every 4 weeks while the body adapts. Your doctor sets your exact schedule.
- Weeks 1–4 · 2.5 mg starting dose
- From week 5 · Step up every 4 weeks as tolerated
- Month 4+ · Personalised maintenance dose
- Ongoing · Quarterly medical reviews
Typical escalation
- Weeks 1–42.5 mg / week
- Step-ups (every 4 weeks)5 → 7.5 → 10 → 12.5 mg
- Maximum dose15 mg / week
Your schedule is personal
These are typical steps only. Your doctor adjusts the plan to how you respond and tolerate it — and you can message them at any point.
Safety first
Safety, in full.
Mounjaro is an effective medicine — and like any medicine it carries risks. Your doctor screens for all of this before prescribing. Here's the honest picture, not just reassurance.
Adults with obesity (BMI ≥30) or with overweight (BMI ≥27) plus at least one weight-related condition.
- Once-weekly self-injection in the thigh, abdomen or upper arm.
- Dose is escalated step-wise (2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg) every 4 weeks while the body adapts.
- Combined with diet and physical activity — tirzepatide complements, not replaces, lifestyle change.
Who should not take it
- Personal or family history of medullary thyroid carcinoma or MEN 2.
- Pregnancy, planned pregnancy in the next 2 months, or breastfeeding.
- History of pancreatitis.
- Type 1 diabetes or diabetic ketoacidosis.
- Severe gastroparesis.
When to seek urgent care
For severe, sudden or unexpected symptoms, call your local emergency number or go to the nearest emergency department. Then let your doctor know through your account chat.
PRICING
Two clear ways to continue your care.
€25/month for weight loss or €15/month (billed €45 every 3 months) for hair growth. €35 one-off is available for sexual health.
ONGOING PLAN
Ongoing treatment plan
Weight loss
€25/month
For ongoing treatment and doctor-reviewed renewals.
Available for weight-loss and hair-growth treatments.
Start consultationWHAT'S INCLUDED
- First consultation included
- Renewals reviewed by your doctor
- Ongoing care with your doctor
- Priority review
- Cancel anytime
Full refund if a review is not approved If a review is not approved, we refund that period's €25 fee and cancel the plan.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
HOW THE DOCTOR DECIDES
A licensed doctor reviews your case, not an algorithm
An EU-licensed doctor reads your questionnaire and answers within 24 hours.
If the doctor decides it is not safe to prescribe, the consultation fee is refunded in full.
Follow-up happens in the private chat inside your account, under GDPR. No WhatsApp, no SMS.
OTHER WEIGHT LOSS TREATMENTS
Explore related treatments.
Find out if it's right for you
See if Mounjaro is appropriate for you.
Answer a few questions and a licensed EU doctor reviews your case within 24 hours. Refunded in full if it's not right for you.
ALSO AVAILABLE IN